BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, recently announced that based on revenue growth from 2015 to 2018, it has been selected for inclusion on the Deloitte 2019 Technology Fast 500 list.
Mike Rice, BioLife President and CEO, commented, “We appreciate this recognition of our revenue growth over the last few years. We are focused on building a much larger, world-class enterprise supplying novel and enabling bioproduction tools to the cell and gene therapy industry.”
About Deloitte’s 2019 Technology Fast 500™
Now in its 25th year, Deloitte’s Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2015 to 2018.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US $50,000, and current-year operating revenues of at least US $5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
